Pharmacological inhibition of MDM2 for stabilization of p53 has been of interest for several years, particularly for cancers with MDM2 amplification, including liposarcoma, Ewing’s sarcoma, osteosarcoma, and leukemia (2, 10–12). This evidence concerns the gene MDM2 and liposarcoma.